. 2020 Nov 17;8:e9998. doi: 10.7717/peerj.9998

Table 3. Baseline factors associated with dapagliflozin response in HbA1c at Month 6 examined by logistic regression analysis.

Parameter	OR	95% CI	pvalue
HbA1c –Univariate
Age (years)	0.99	(0.98, 1.01)	0.277
Gender, female	1.20	(0.94, 1.53)	0.138
Weight (kg)	1.00	(0.99, 1.01)	0.594
BMI (kg/m²)	1.01	(0.99, 1.04)	0.357
HbA1c (%)	2.12	(1.87, 2.41)	<0.001
FPG (mg/dL)	1.01	(1.00, 1.01)	<0.001
SBP (mmHg)	1.00	(0.99, 1.01)	0.955
Add-on dapagliflozin	1.31	(1.03, 1.67)	0.029
Number of antihyperglycemic drug
Monotherapy	0.76	(0.47, 1.24)	0.273
Dual therapy	0.66	(0.45, 0.98)	0.037
Triple therapy	0.72	(0.49, 1.06)	0.098
Antihyperglycemic therapy
Insulin	1.58	(1.20, 2.07)	0.001
HbA1c –Multivariate
HbA1c (%)	2.10	(1.79, 2.47)	<0.001
FPG (mg/dL)	1.00	(1.00, 1.01)	0.349
Add-on dapagliflozin	1.60	(1.19, 2.14)	0.002
Number of antihyperglycemic drug
Monotherapy	1.40	(0.78, 2.50)	0.255
Dual therapy	0.94	(0.58, 1.52)	0.804
Triple therapy	0.95	(0.59, 1.54)	0.844
Antihyperglycemic therapy
Insulin	0.83	(0.59, 1.18)	0.298

Notes.

Responders and non-responders were determined by using the median of change in HbA1c (−0.60%) as the cutoff.

Abbreviations